

Peter C Adamson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6935214/publications.pdf>

Version: 2024-02-01

185
papers

10,087
citations

38660

50
h-index

39575

94
g-index

189
all docs

189
docs citations

189
times ranked

11306
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. <i>Neuro-Oncology</i> , 2022, 24, 655-664.	0.6	24
2	Reply to R. Lakhotia et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102912.	0.8	0
3	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. <i>European Journal of Cancer</i> , 2022, 166, 145-164.	1.3	28
4	My Patient Portal. <i>Annals of Internal Medicine</i> , 2022, 175, 905.	2.0	1
5	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). <i>Clinical Cancer Research</i> , 2021, 27, 3543-3548.	3.2	59
6	Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3716-3724.	0.8	18
7	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
8	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 829-840.	1.1	22
9	Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. <i>New England Journal of Medicine</i> , 2020, 382, 2207-2219.	13.9	157
10	Pediatric cancer research: Surviving COVID-19. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28435.	0.8	28
11	Early Phase Pediatric Cancer Trials: Progress Highlights Challenges. <i>Oncologist</i> , 2020, 25, 468-469.	1.9	1
12	Survivorship Care Plans and the Commission on Cancer Standards: The Increasing Need for Better Strategies to Improve the Outcome for Survivors of Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 447-450.	1.4	29
13	A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7568-TPS7568.	0.8	4
14	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27869.	0.8	57
15	Emergent Radiation for Leukemic Optic Nerve Infiltration in a Child Receiving Intrathecal Methotrexate. <i>Practical Radiation Oncology</i> , 2019, 9, 226-230.	1.1	3
16	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27747.	0.8	40
17	Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine-based estimates of renal function. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27672.	0.8	4
18	The Children's Oncology Group: Organizational Structure, Membership, and Institutional Characteristics. <i>Journal of Pediatric Oncology Nursing</i> , 2019, 36, 24-34.	1.5	12

#	ARTICLE	IF	CITATIONS
19	Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.. Journal of Clinical Oncology, 2019, 37, 10011-10011.	0.8	25
20	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli-Derived Asparaginases. Blood, 2019, 134, 2586-2586.	0.6	0
21	Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. Bone, 2018, 109, 276-280.	1.4	34
22	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2018, 65, e26873.	0.8	48
23	New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics. JAMA Oncology, 2018, 4, 1274.	3.4	22
24	The challenge of pediatric oncology: New business models to accelerate innovation.. Journal of Clinical Oncology, 2018, 36, 10528-10528.	0.8	0
25	Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. Pediatric Blood and Cancer, 2017, 64, e26636.	0.8	23
26	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. Journal of the National Cancer Institute, 2017, 109, .	3.0	85
27	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica, 2017, 102, e340-e343.	1.7	4
28	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2017, 35, 139-140.	0.8	22
29	The 2016 ASPHO Distinguished Career Award Goes to David G. Poplack, MD. Pediatric Blood and Cancer, 2016, 63, S5-S6.	0.8	0
30	When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab. Pediatric Blood and Cancer, 2016, 63, 962-963.	0.8	8
31	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genetics, 2016, 209, 182-194.	0.2	38
32	CYP2B6 or Not CYP2B6 That Remains a Question for Precision Medicine and Ketamine!. Anesthesiology, 2016, 125, 1085-1087.	1.3	4
33	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 1537-1543.	0.8	47
34	Current approach and recommendations for standardized dosing of anticancer drugs in infants.. Journal of Clinical Oncology, 2016, 34, 10546-10546.	0.8	0
35	The impact of chemotherapy shortages on COG and local clinical trials: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 940-944.	0.8	19
36	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1775-1781.	0.8	21

#	ARTICLE	IF	CITATIONS
37	Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1171-1175.	0.8	89
38	Growth plate abnormalities in pediatric cancer patients undergoing phase 1 antiangiogenic therapy: A report from the children's oncology group phase I consortium. <i>Pediatric Blood and Cancer</i> , 2015, 62, 45-51.	0.8	27
39	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 278-284.	0.8	102
40	Improving the outcome for children with cancer: Development of targeted new agents. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 212-220.	157.7	99
41	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	1.1	16
42	Drug discovery in paediatric oncology: roadblocks to progress. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 732-739.	12.5	28
43	Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-51: A report from the Children's Oncology Group (ANBL0621). <i>Pediatric Blood and Cancer</i> , 2014, 61, 990-996.	0.8	16
44	The Children's Oncology Group Childhood Cancer Research Network (CCRN): Case catchment in the United States. <i>Cancer</i> , 2014, 120, 3007-3015.	2.0	27
45	It seemed like a good idea at the time. <i>Pediatric Blood and Cancer</i> , 2014, 61, 187-188.	0.8	0
46	Too Few Medicines for Children With Cancer"Reply. <i>JAMA Pediatrics</i> , 2014, 168, 583.	3.3	0
47	Reply to N.-K.V. Cheung et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 4174-4175.	0.8	6
48	Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 452-456.	0.8	132
49	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. <i>Clinical Cancer Research</i> , 2014, 20, 4200-4209.	3.2	127
50	Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2014, 61, 145-150.	0.8	56
51	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 833-839.	0.8	87
52	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	0.8	91
53	A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 971, 30-34.	1.2	1
54	Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence. <i>Progress in Pediatric Cardiology</i> , 2014, 36, 39-49.	0.2	34

#	ARTICLE	IF	CITATIONS
55	Declining childhood and adolescent cancer mortality. <i>Cancer</i> , 2014, 120, 2497-2506.	2.0	410
56	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 7086-7086.	0.8	0
57	Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2013, 60, 237-241.	0.8	34
58	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 472-480.	5.1	614
59	Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. <i>Epilepsia</i> , 2013, 54, 141-155.	2.6	219
60	New drugs for children and adolescents with cancer: the need for novel development pathways. <i>Lancet Oncology</i> , The, 2013, 14, e117-e124.	5.1	81
61	Quantification of Serum Fentanyl Concentrations From Umbilical Cord Blood During Ex-Utero Intrapartum Therapy. <i>Survey of Anesthesiology</i> , 2013, 57, 75.	0.1	0
62	Unintended Consequences of Regulatory Initiatives in Childhood Cancer Drug Development. <i>JAMA Pediatrics</i> , 2013, 167, 886.	3.3	15
63	The Children's Oncology Group's 2013 five year blueprint for research. <i>Pediatric Blood and Cancer</i> , 2013, 60, 955-956.	0.8	21
64	Imaging in childhood cancer: A society for pediatric radiology and children's oncology group joint task force report. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1253-1260.	0.8	42
65	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2012, 18, 5081-5089.	3.2	22
66	Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study. <i>Clinical Cancer Research</i> , 2012, 18, 6058-6064.	3.2	110
67	Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031. <i>Clinical Cancer Research</i> , 2012, 18, 1547-1554.	3.2	16
68	A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2012, 18, 6011-6022.	3.2	103
69	Quantification of Serum Fentanyl Concentrations from Umbilical Cord Blood During Ex Utero Intrapartum Therapy. <i>Anesthesia and Analgesia</i> , 2012, 114, 1265-1267.	1.1	14
70	Sporadic Adenocarcinoma of the Colon in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e137-e141.	0.3	30
71	Challenges and opportunities in childhood cancer drug development. <i>Nature Reviews Cancer</i> , 2012, 12, 776-782.	12.8	48
72	Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: A Children's Oncology Group trial (P9962). <i>Pediatric Blood and Cancer</i> , 2012, 58, 362-365.	0.8	25

#	ARTICLE	IF	CITATIONS
73	Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1021-1027.	1.1	31
74	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9500-9500.	0.8	29
75	Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium. <i>Journal of Clinical Oncology</i> , 2011, 29, 839-844.	0.8	100
76	A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. <i>Neuro-Oncology</i> , 2011, 13, 910-915.	0.6	28
77	Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1469-1475.	1.1	16
78	Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 56, 226-233.	0.8	21
79	Preclinical evaluation of pemetrexed in pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1233-1235.	0.8	2
80	Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report. <i>Clinical Cancer Research</i> , 2011, 17, 589-597.	3.2	92
81	Reply to P.A. Meyers et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e181-e181.	0.8	0
82	Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2011, 17, 5113-5122.	3.2	104
83	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. <i>Blood</i> , 2011, 118, 573-573.	0.6	21
84	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. <i>Blood</i> , 2011, 118, 2617-2617.	0.6	0
85	Approaches to Clear Residual Chemotherapeutics From Indwelling Catheters in Children With Cancer. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 741-748.	1.0	10
86	Population Pharmacokinetics of Dexmedetomidine in Infants After Open Heart Surgery. <i>Anesthesia and Analgesia</i> , 2010, 110, 1383-1392.	1.1	67
87	Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1125-1130.	1.1	14
88	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 737-743.	1.1	16
89	Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1 to 48 months. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 77-86.	0.8	23
90	A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2369-2373.	1.2	7

#	ARTICLE	IF	CITATIONS
91	It's not easy being small. <i>Pediatric Blood and Cancer</i> , 2010, 54, 341-343.	0.8	11
92	Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. <i>Pediatric Blood and Cancer</i> , 2010, 54, 538-545.	0.8	68
93	Reasons for participation in optional pharmacokinetic studies in children with cancer: A Children's Oncology Group phase I consortium study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 119-122.	0.8	14
94	A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 440-445.	0.8	45
95	Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 629-638.	0.8	53
96	A pediatric phase I trial and pharmacokinetic study of ispinesib: A Children's Oncology Group phase I consortium study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1323-1328.	0.8	43
97	A Phase I Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan-VEGFR Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 5174-5181.	0.8	98
98	Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 3979-3986.	0.8	130
99	Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2010, 16, 750-754.	3.2	41
100	Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy. <i>New England Journal of Medicine</i> , 2010, 362, 790-799.	13.9	558
101	Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1450-1456.	1.4	82
102	Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors. <i>Cancer</i> , 2009, 115, 1765-1775.	2.0	15
103	Imaging in early phase childhood cancer trials. <i>Pediatric Radiology</i> , 2009, 39, 38-41.	1.1	5
104	A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report. <i>Pediatric Blood and Cancer</i> , 2009, 53, 978-983.	0.8	89
105	Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 717-723.	1.1	101
106	Stress lysis in childhood leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 137-139.	0.8	0
107	A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2008, 50, 254-258.	0.8	186
108	A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2008, 50, 577-580.	0.8	28

#	ARTICLE	IF	CITATIONS
109	Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: A Children's Oncology Group report. <i>Pediatric Blood and Cancer</i> , 2008, 50, 533-536.	0.8	2
110	A rapid, sensitive and selective liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry method for determination of fenretinide (4-HPR) in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 862, 64-71.	1.2	7
111	Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. <i>British Journal of Haematology</i> , 2008, 141, 827-839.	1.2	44
112	The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: A multicenter, double-blind, randomized trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 321-328.	0.4	72
113	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3756-3762.	0.8	211
114	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1111-1115.	3.2	45
115	Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4921-4927.	0.8	113
116	Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design. <i>Journal of Clinical Oncology</i> , 2008, 26, 190-195.	0.8	223
117	Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials. <i>Oncologist</i> , 2008, 13, 679-689.	1.9	54
118	Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 399-405.	0.8	240
119	Text on Randomized Clinical Trials in Pediatric Oncology. <i>Oncologist</i> , 2008, 13, 93-94.	1.9	0
120	Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study. <i>Neuro-Oncology</i> , 2008, 10, 752-758.	0.6	47
121	A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. <i>Neuro-Oncology</i> , 2008, 10, 569-576.	0.6	27
122	Population Pharmacokinetic Investigation of Actinomycin D in Children and Young Adults. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 35-42.	1.0	23
123	Phase I trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. <i>Blood</i> , 2008, 111, 566-573.	0.6	113
124	Lenalidomide (LMiD) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Blood</i> , 2008, 112, 107-107.	0.6	4
125	Current challenges in pediatric drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 883-4.	0.3	1
126	A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin's Lymphoma: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 5652s-5660s.	3.2	31

#	ARTICLE	IF	CITATIONS
127	A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 1789-1793.	3.2	106
128	A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 1516-1522.	3.2	142
129	Tyrosine Kinase Inhibitors in Pediatric Malignancies. <i>Cancer Investigation</i> , 2007, 25, 606-612.	0.6	11
130	A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. <i>Journal of Mass Spectrometry</i> , 2007, 42, 761-770.	0.7	23
131	Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). <i>Pediatric Blood and Cancer</i> , 2007, 49, 250-255.	0.8	26
132	A phase 2 trial of all-trans-retinoic acid in combination with interferon- γ 2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. <i>Pediatric Blood and Cancer</i> , 2007, 49, 661-665.	0.8	39
133	Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. <i>Pediatric Blood and Cancer</i> , 2007, 49, 687-693.	0.8	9
134	Case study. All for one, or one for all? Commentary. <i>Hastings Center Report</i> , 2007, 37, 13-4.	0.7	0
135	Understanding and Managing Methotrexate Nephrotoxicity. <i>Oncologist</i> , 2006, 11, 694-703.	1.9	591
136	Anticancer effects of fenretinide in human medulloblastoma. <i>Cancer Letters</i> , 2006, 231, 262-269.	3.2	14
137	Population Pharmacokinetics of Milrinone in Neonates with Hypoplastic Left Heart Syndrome Undergoing Stage I Reconstruction. <i>Anesthesia and Analgesia</i> , 2006, 102, 1062-1069.	1.1	58
138	Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2006, 47, 790-794.	0.8	36
139	The Pharmacokinetics of Esmolol in Pediatric Subjects with Supraventricular Arrhythmias. <i>Pediatric Cardiology</i> , 2006, 27, 420-427.	0.6	39
140	A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 458-464.	1.1	31
141	A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2006, 12, 1750-1759.	3.2	176
142	A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4882-4887.	3.2	45
143	Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2006, 24, 3678-3685.	0.8	81
144	Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children's Oncology Group (COG) Study. <i>Blood</i> , 2006, 108, 2585-2585.	0.6	2

#	ARTICLE	IF	CITATIONS
145	The Bioavailability of Oral Methotrexate in Children with Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, 445-449.	0.9	29
146	Drug Utilization in the Pediatric Intensive Care Unit: Monitoring Prescribing Trends and Establishing Prioritization of Pharmacotherapeutic Evaluation of Critically Ill Children. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1305-1312.	1.0	29
147	New Approaches to Drug Development in Pediatric Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 324-330.	1.0	18
148	THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DEXMEDETOMIDINE IN INFANTS FOLLOWING OPEN HEART SURGERY.. <i>Critical Care Medicine</i> , 2005, 33, A6.	0.4	4
149	Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency. <i>Journal of Clinical Oncology</i> , 2005, 23, 8431-8441.	0.8	113
150	RESPONSE: Re: Treatment of Accidental Intrathecal Methotrexate Overdose. <i>Journal of the National Cancer Institute</i> , 2005, 97, 610-611.	3.0	2
151	Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4536-4545.	1.4	265
152	Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6172-6180.	0.8	98
153	Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense™ (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.. <i>Blood</i> , 2005, 106, 3360-3360.	0.6	1
154	Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.. <i>Blood</i> , 2005, 106, 3368-3368.	0.6	1
155	Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special Imperatives. <i>Journal of Clinical Oncology</i> , 2004, 22, 4846-4850.	0.8	32
156	Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1557-1559.	3.0	60
157	Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015). <i>Journal of Clinical Oncology</i> , 2004, 22, 4804-4809.	0.8	110
158	Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. <i>Pediatric Blood and Cancer</i> , 2004, 43, 780-784.	0.8	39
159	The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs. <i>Biopharmaceutics and Drug Disposition</i> , 2004, 25, 265-271.	1.1	8
160	The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. <i>Critical Care Medicine</i> , 2004, 32, 2318-2322.	0.4	77
161	Congenital Neuroblastoma Arising in the Deltoid Muscle. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 101-103.	0.3	3
162	A tale of three princes and two physicists?the importance of ?Why??. <i>Medical and Pediatric Oncology</i> , 2003, 41, 132-135.	1.0	2

#	ARTICLE	IF	CITATIONS
163	Liquid chromatography-electrospray mass spectrometry (LC-MS) method for determination of esmolol concentration in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 796, 293-301.	1.2	6
164	Propofol pharmacokinetics *. <i>Pediatric Critical Care Medicine</i> , 2003, 4, 124-125.	0.2	6
165	The importance of pharmacokinetic limited sampling models for childhood cancer drug development. <i>Clinical Cancer Research</i> , 2003, 9, 5068-77.	3.2	21
166	THE EFFECTS OF CARDIOPULMONARY BYPASS (CPB) AND MODIFIED ULTRAFILTRATION (MUF) ON THE PLASMA PHARMACOKINETICS OF MILRINONE (MLR) IN NEONATES WITH HYPOPLASTIC LEFT HEART SYNDROME (HLHS). <i>Critical Care Medicine</i> , 2002, 30, A155.	0.4	2
167	Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations. <i>Journal of Clinical Oncology</i> , 2001, 19, 2754-2763.	0.8	44
168	Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 41-44.	1.1	50
169	Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 235-240.	1.1	8
170	Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 275-282.	1.1	37
171	A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. <i>Clinical Cancer Research</i> , 2001, 7, 3034-9.	3.2	14
172	Proton Magnetic Resonance Spectroscopic Imaging in Children With Recurrent Primary Brain Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 1020-1020.	0.8	99
173	Application of Pharmacogenetics to Optimization of Mercaptopurine Dosing. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1983-1985.	3.0	21
174	The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex TM) in a nonhuman primate model. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 439-443.	1.1	26
175	Successful Treatment of Intrathecal Methotrexate Overdose by Using Ventriculolumbar Perfusion and Intrathecal Instillation of Carboxypeptidase G2. <i>Mayo Clinic Proceedings</i> , 1996, 71, 161-165.	1.4	47
176	Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. <i>Cancer</i> , 1995, 76, 521-526.	2.0	63
177	Acute pancreatitis after ifosfamide therapy. <i>Cancer</i> , 1994, 74, 1627-1628.	2.0	22
178	The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 1994, 18, 805-810.	0.4	55
179	Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. <i>Biochemical Pharmacology</i> , 1993, 45, 1493-1501.	2.0	12
180	Desulfuration of 6-mercaptopurine. <i>Biochemical Pharmacology</i> , 1993, 46, 1627-1636.	2.0	5

#	ARTICLE	IF	CITATIONS
181	A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 155-157.	1.1	5
182	The Child with Recurrent Solid Tumor. <i>Pediatric Clinics of North America</i> , 1991, 38, 489-504.	0.9	3
183	A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 343-344.	1.1	27
184	Pertussis in a previously immunized child with human immunodeficiency virus infection. <i>Journal of Pediatrics</i> , 1989, 115, 589-592.	0.9	36
185	Amphotericin B in the treatment of <i>Candida</i> cholecystitis. <i>Pediatric Infectious Disease Journal</i> , 1989, 8, 408-410.	1.1	24